Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27544345 | 1.00 | SLC7A5 (0.48) | SLC7A5KDM4EUSP2EGFRLCK | |
| SCHEMBL5108519 | 0.87 | ALDH1A1 (0.51) | SLC7A5KDM4EUSP2EGFRLCK | |
| Etilevodopa SCHEMBL1069939 | 0.87 | ALOX15 (0.64) | SLC7A5KDM4EUSP2EGFRLCK | |
| Etilevodopa SCHEMBL29634876 | 0.87 | ALOX15 (0.64) | SLC7A5KDM4EUSP2EGFRLCK | |
| Etilevodopa SCHEMBL584493 | 0.87 | ALOX15 (0.64) | SLC7A5KDM4EUSP2EGFRLCK | |
| Hydrochloric Acid SCHEMBL5108514 | 0.86 | ALDH1A1 (0.53) | SLC7A5KDM4EUSP2EGFRLCK | |
| Etilevodopa SCHEMBL7291700 | 0.85 | ALOX15 (0.62) | SLC7A5KDM4EUSP2EGFRLCK | |
| Etilevodopa SCHEMBL28278862 | 0.85 | ALOX15 (0.62) | SLC7A5KDM4EUSP2EGFRLCK | |
| Etilevodopa SCHEMBL7063390 | 0.85 | ALOX15 (0.62) | SLC7A5KDM4EUSP2EGFRLCK | |
| SCHEMBL30665444 | 0.84 | SLC7A5 (0.49) | SLC7A5KDM4EUSP2EGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124824-B1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2007-08-22 | — | — | EP | disclosed |
| CN-1301964-C | Inhibitors of alpha 4-mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1049662-B1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6855843-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-6849646-B1 | Chromenone and chromanone derivatives as integrin inhibitors | MERCK PATENT GMBH (DE) | 2005-02-01 | — | — | US | disclosed |
| CN-1150189-C | Benzopyrone and chromanone derivatives as integrin inhibitors | Ĭ��ר���ɷ�����˾ | 2004-05-19 | — | — | CN | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-1124824-A1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GmbH (DE) | 2001-08-22 | — | — | EP | disclosed |
| CN-1288457-A | Inhibitors of & alpha, 4 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2001-03-21 | — | — | CN | disclosed |
| WO-2000026212-A1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | SLC7A5 1025/4885KDM4E 1736/4885USP2 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.